Cellectis (CLLS) Change in Acquisitions & Divestments (2021)
Cellectis (CLLS) posted quarterly Change in Acquisitions & Divestments of -$105.4 million for Q2 2024, down 6128.9% quarter-over-quarter from -$1.7 million in Q1 2024.
Analysis
Cellectis (CLLS) Change in Acquisitions & Divestments (2021) Analysis & Trends
Cellectis' Change in Acquisitions & Divestments history runs 8 years deep, the most recent figure standing at -$105.4 million for Q2 2024.
- In Q2 2024, Change in Acquisitions & Divestments changed N/A year-over-year to -$105.4 million; the TTM figure through Jun 2024 stood at -$107.0 million (changed N/A YoY), while the FY2023 annual figure was -$13.4 million, changed N/A from the prior year.
- Change in Acquisitions & Divestments for Q2 2024 stood at -$105.4 million, down from -$1.7 million in the prior quarter.
- The five-year high for Change in Acquisitions & Divestments was $25.9 million in Q4 2020, with the low at -$105.4 million in Q2 2024.
- The 4-year median for Change in Acquisitions & Divestments is $1.7 million (2021), against an average of -$7.3 million.
- Peak annual rise in Change in Acquisitions & Divestments reached 862800.0% in 2020, while the deepest fall reached 23939.51% in 2020.
- Cellectis' Change in Acquisitions & Divestments stood at $25.9 million in 2020, then slumped by 145.25% to -$11.7 million in 2021, then soared by 97.21% to -$326000.0 in 2022, then tumbled by 32229.14% to -$105.4 million in 2024.
- Business Quant data shows CLLS's Change in Acquisitions & Divestments at -$105.4 million in Q2 2024, -$1.7 million in Q1 2024, and -$326000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - |